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ABSTRACT
Background: Health utility data often show an apparent truncation effect,
where a proportion of individuals achieve the upper bound of 1. The Tobit
model and censored least absolute deviations (CLAD) have both been used
as analytic solutions to this apparent truncation effect. These models
assume that the observed utilities are censored at 1, and hence that the true
utility can be greater than 1.We aimed to examine whether the Tobit and
CLAD models yielded acceptable results when this censoring assumption
was not appropriate.
Methods: Using health utility (captured through EQ5D) data from a
diabetes study, we conducted a simulation to compare the performance of
the Tobit, CLAD, ordinary least squares (OLS), two-part and latent class
estimators in terms of their bias and estimated conﬁdence intervals. We
also illustrate the performance of semiparametric and nonparametric
bootstrap methods.
Results: When the true utility was conceptually bounded above at 1, the
Tobit and CLAD estimators were both biased. The OLS estimator was
asymptotically unbiased and, while the model-based and semiparametric
bootstrap conﬁdence intervals were too narrow, conﬁdence intervals based
on the robust standard errors or the nonparametric bootstrap were accept-
able for sample sizes of 100 and larger. Two-part and latent class models
also yielded unbiased estimates.
Conclusions: When the intention of the analysis is to inform an economic
evaluation, and the utilities should be bounded above at 1, CLAD, and
Tobit methods were biased. OLS coupled with robust standard errors or
the nonparametric bootstrap is recommended as a simple and valid
approach.
Keywords: CLAD, economic evaluation, nonnormality, Tobit, Utility.
1. Introduction
The quality-adjusted life-year (QALY) is a preferred outcome
measure in economic evaluations as it incorporates both quantity
and quality of life, thus allowing for comparisons across diseases
[1,2]. The QALY can be calculated by multiplying the quality
weight of a health state by the time spent in that state. Utility can
be used as quality weight in economic evaluations and it is
commonly estimated using existing multi-attribute health classi-
ﬁcation systems (also known as preference-based health-related
quality of life (HRQoL) instruments), for example the Health
Utility Index (HUI) [3,4] and the EQ5D [5]. In addition to
preference-based instruments, there are proﬁle-based instruments
(either generic or disease-speciﬁc) used to measure HRQoL.
When analyzing HRQoL or a health utility, it is important to
check that the distributional assumptions of the analysis method
are met by the data. A common property of utility data is that the
distribution is often nonnormal, with a left-skew and apparent
truncation at 1 (i.e., a proportion of the population may achieve
the upper bound of 1, depending on the population of interest).
Simple linear regression is a common analysis technique which
requires that the residuals of the regression be normally distrib-
uted. In the case of substantial truncation or bimodality of the
utilities themselves, normality of the residuals may not hold.
Alternative analytic techniques are Tobit models [6,7], censored
least absolute deviations (CLAD) models [6,7], two-part models
(TPMs), and latent class models (LCMs) for the analysis of such
data [8]. Simulation studies have compared these methods head-
to-head (ordinary least squares (OLS), Tobit, and CLAD in [6],
OLS, CLAD, two-part, and LCMs in [8]). However, the CLAD
and Tobit approaches model something quite different to the
other models, and previous comparisons between the methods
have often not discussed the key conceptual differences between
them (see, for example [8]).
Whereas the two-part and LCMs take various approaches to
dealing with the conditional nonnormality in the data, the Tobit
and CLAD models treat the distribution as censored at 1. That is,
they assume that the underlying measurement can extend beyond
1, but that the measurement instrument incorrectly truncates the
distribution at 1. In this article, we shall make a clear distinction
between health utilities and HRQoL, and will argue that health
utilities should not usually be treated as censored. We will show
through a simulation study that linear regression coupled with
the nonparametric bootstrap is quite adequate for the analysis of
health utility data. We will also compare the performance of the
OLS, Tobit, CLAD, two-part, and LCMs.
The remainder of this article is organized as follows: Section
2 outlines the philosophical differences between a health utility
and HRQoL and discusses some measurement issues; Section 3
describes some analysis approaches; Section 4 describes the
set-up of a simulation study to illustrate the importance of select-
ing a method that is appropriate to the desired outcome; Section
5 presents the results of the study; and Section 6 offers some
conclusions.
2. Concepts and Measurement
For the purposes of this article, it is helpful to make a clear
distinction between a health utility and HRQoL. Before discussing
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analysis issues, we shall ﬁrst discuss whether it is a health utility or
HRQoL that is the outcome of interest, and then consider mea-
surement issues.
Health utility is a quality weight used to calculate a QALY.
Health utilities can be derived using different elicitation tech-
niques, including the visual analog scale, standard gamble (SG),
and time trade-off (TTO), with 0 representing death and 1 rep-
resenting full health. These elicitation techniques ensure that the
weights have ratio properties, i.e., a utility of 0.5 is worth half as
much as a utility of 1. Negative utilities are allowed because there
are health states worse than death; however, utilities cannot
exceed 1 because you cannot do better than full health [9].
In contrast, HRQoL is a broader and a more abstract con-
struct that captures an individual’s well-being. There is no bound
set to HRQoL measurements. Different instruments developed
over different scales will result in different score boundaries. For
example, the Short Form 36 (SF-36) bodily pain domain score
ranges from 0 to 100 [10], while the Western Ontario and
McMaster Universities Osteoarthritis Index pain domain score
ranges from 0 to 20 [11].
Turning now to the measurement issue, many instruments
used to capture health utilities have the property that a portion of
the population achieves the upper bound of 1. This phenomenon
is often described in the literature as “censoring,” “truncation,”
or a “ceiling effect.” Implicit in each of these terms is that the true
measurement can exceed 1. However, this is not the only manner
in which the data distribution can arise. An alternate explanation
is that the measurement instrument is not able to capture small
departures from perfect health.
It is not possible to capture all health states using a short
questionnaire. For example, the EQ5D asks just ﬁve questions.
While it is clearly impossible to assess a person’s well-being
comprehensively using a generic instrument and based on such
little information, accurate measurement must be balanced with
the need to make questionnaires simple enough to be practical. If
we are interested in a utility, we must recognize that these mea-
sures are approximations only and are insensitive to small depar-
tures from perfect health. We stress, however, that this is a
measurement issue rather than a censoring issue. In healthy popu-
lations, instead of seeing a large number of values clustered
slightly below one, we see a large number of values that are exactly
one. If values were censored at one, we would see a proportion of
values that achieve that bound, but it would be possible to exceed
that bound. For a utility, this is by deﬁnition impossible: you
cannot exceed full health. On the other hand, if we are interested
in HRQoL as a more abstract construct, then we can acknowledge
that our measurement scale does not distinguish well between
normal and perfect health, and hence we can take values of one to
indicate normal health and treat the measure as censored, so that
some individuals can have “supranormal” health [12].
Analysis decisions become clearer once it has been decided
whether it is a utility or the HRQoL construct that is of interest.
Although HRQoL is often an important outcome in its own
right, in the context of an economic evaluation in which costs are
to be weighed against effects and the measure of effectiveness is
a QALY (i.e., a cost–utility analysis in particular), it is the utility
rather than HRQoL that is the outcome of interest. We now
describe appropriate methods of analysis for each outcome.
3. Analysis Methods
Here, we review the various methods that have been proposed
for the analysis of health utility data. There are two broad
categories of models: the ﬁrst category assumes the data is cen-
sored at 1, while the second assumes no censoring but must
address the nonnormality of the data. The methods are outlined
in Table 1, and summarized below.
The Tobit and CLAD models assume that the true values can
extend beyond one but are observed subject to censoring at one.
The Tobit model handles this censoring by assuming that the true
value has a normal distribution whose mean is given by a linear
combination of the covariates. The CLAD model assumes that
the median is a linear combination of the covariates, but leaves
the distribution otherwise unspeciﬁed. When making the censor-
ing assumption, it is implicit that it is HRQoL rather than a
health utility that is the outcome of interest.
When it is a utility that is the outcome of interest, the assump-
tion is that the true utility score has a maximum of 1. Thus the
question is not how to deal with the censoring, but rather how to
deal with the nonnormality. OLS applied to marginal linear
regression models handles this by modeling the mean utility only,
and makes no assumptions about the remainder of the distribu-
tion. TPMs speciﬁcally model the probability of attaining the
upper bound, and then model the remainder of the distribution
below this bound using a regression model, sometimes after
applying a log transform. LCMs assume that there is an unob-
served variable which splits the population into two, and that the
distribution of utilities within each population is normal. TPMs
may thus be more helpful when a large proportion of the popu-
lation achieve a utility of 1, whereas LCMs may be more useful
when the distribution of observed utilities is bimodal, with both
modes falling below 1.
We now describe each method in detail.
Models Assuming Censoring, and Hence Candidates for
the Analysis of HRQoL Subject to Ceiling Effects
Tobit. The ﬁrst model that we shall consider is the Tobit model.
This was developed by Tobin, and assumes that there is a latent
HRQoL Yi* satisfying
Y Xi i i* *= +β ε
with ε σi N* ,∼ 0 2( ), but that instead of observing Yi*, we instead
observe Yi*, deﬁned as
Y Y Yi i i= ≤* if 1
Yi = 1 otherwise
This is the same model as an accelerated failure time model and
can thus be ﬁtted by any procedure that ﬁts a parametric survival
analysis using a normal distribution for the failure time. In the
Tobit model, it is the latent HRQoL Yi*, rather than the utility Yi
that is modeled.
In a simulation study, Austin et al. [7] demonstrated that the
Tobit model is less biased than OLS when the error terms are
homoscedastic (even if they are nonnormal). We note, however,
that this was because the data were simulated so that the true
health status could be larger than 1, depended linearly on the
covariate (age), but was censored at 1. Thus, OLS was biased
when the “true” regression coefﬁcient was that used for the
simulation, i.e., for health states that could be supranormal.
Whether or not OLS is actually biased depends on whether you
consider health states larger than 1 to be valid and of interest.
Austin et al. [7] caution that the Tobit model can give misleading
results in the presence of heteroscedascity.
Censored least absolute deviations. The CLAD approach is a
solution to the Tobit model’s sensitivity to heteroscedascity, and
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has been shown to yield consistent estimates under certain con-
ditions. Like the Tobit model, CLAD assumes that HRQoL
values measured to be 1 have in fact been censored, and accounts
for this in the estimation. In contrast to the Tobit model, CLAD
models medians rather than means: rather than minimizing a
sum of squares, it minimizes the sum of absolute deviations given
by
Y Xi i
i
n
− ( )
=
∑ min ,1
1
β
Note that if interest lies in modeling QALYs in order to
conduct an economic evaluation, it is the mean, not the median,
that is of interest [13]. However, if the error distribution of the
uncensored utility values is symmetric, the mean and the median
will coincide.
Previous work [6] has recommended the use of CLAD over
OLS, as it has a smaller absolute prediction error. However,
because CLAD is a median regression and OLS is a mean regres-
sion, it is not surprising that CLAD should have a smaller abso-
lute prediction error—the question is whether or not it has a
smaller mean square prediction error. Work by Huang et al. [8]
suggests that CLAD predicts a smaller percentage of both abso-
lute and square error than OLS.
It is important to note that both the Tobit and the CLAD
methods model the latent Yi*, i.e., a HRQoL, of which the
observed utility is assumed to be an imperfect observation (spe-
ciﬁcally, an observation that is subject to censoring at 1).
Models with No Censoring, and Hence Candidates for
the Analysis of Health Utilities
Linear regression, marginal mean models, and OLS. Conven-
tional linear regression is fully parametric, that is, it places a
distribution on the utilities. If Yi is the measure of utility for
individual i and Xi is a vector of covariates, then a typical linear
regression model is
Y Xi i i= +β ε (3.1)
with ε σi N* ,∼ 0 2( ). This model thus assumes that the errors are
normally distributed and homoscedasctic (i.e., that their variance
is the same for all i). Under this standard linear regression model,
Y, given X, is normal with mean Xb and variance s2. The
regression coefﬁcients b can be estimated by maximum likeli-
hood, and so minimize
Y Xi i
i
n
−( )
=
∑ β 2
1
(3.2)
Hence βˆ solves Y X Xi i
i
n
i−( ) =
=
∑ β
1
0.
Normality of the distribution of βˆ follows from conditional
normality of Y, and this allows for calculation of P-values and
conﬁdence intervals. It is a familiar result that βˆ is the best linear
unbiased estimator (BLUE) for b.
However, the measured utility is bounded at 1, and hence the
assumption that Y is normally distributed conditionally on cova-
riates will not usually hold (this assumption can be checked by
examining q–q plots of the residuals from the linear model).
Moreover, unlike other outcomes (e.g., intelligence quotient,
height) which are also bounded, because individuals will some-
times achieve the upper bound, conditional normality is often not
even approximately achieved. A simple solution to this problem
is to make a small change to the model. Rather than using the
model (3.1), we instead takeTa
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E Y X Xi i i( ) = β (3.3)
This is similar to (3.1) in terms of the marginal mean model;
however, in this case we do not assume that the distribution of
Y given X is normal. Motivated by the maximum likelihood
estimator (3.2), we take βˆ to minimize the sum of squares, i.e., as
before βˆ solves Y X Xi i
i
n
i−( ) =
=
∑ β
1
0. This procedure is called OLS.
Because model (3.3) makes fewer assumptions than model (3.1),
βˆ loses some of its properties. It is no longer guaranteed to be
unbiased or normal, making calculation of P-values and conﬁ-
dence intervals more challenging. However, the central limit
theorem can be used to show that βˆ is both asymptotically
unbiased (i.e., consistent) and asymptotically normal. Note that
because the estimation procedures for linear regression and the
marginal model are identical, any procedure for linear regression
will ﬁt the marginal model; however, the resulting P-values and
conﬁdence intervals will be valid only if the sample size is sufﬁ-
ciently large and the error terms are identically distributed.
Bootstrap. This last statement poses two difﬁculties. First, the
term “sufﬁciently large” is not well deﬁned. The answer to the
question “How large is large enough?” depends on to what
degree the assumptions of the conventional linear regression
model are violated. At one extreme, if the data is perfectly
normal, the only sample size requirement is that there are sufﬁ-
ciently many observations to ﬁt the required model, and for the
sample to be representative of the population of interest. At the
other extreme, an outcome variable that is heavily skewed may
require a sample size of thousands before the sampling distribu-
tion of βˆ begins to approach normality. Generally speaking, the
greater the degree of nonnormality, the larger the required
sample size for asymptotic results to begin to apply.
Second, error terms from a linear regression of utility data are
unlikely to be identically distributed, because individuals with
higher scores also tend to have scores that are less variable, so
that the data shows heteroscedascity. This is a consequence of the
ceiling effect: individuals with normal but imperfect health will
tend to have utilities close to 1, whereas individuals with poorer
health could take on a wider range of utilities less than 1.
A useful method of deriving valid P-values and conﬁdence
intervals in the face of these difﬁculties is the bootstrap. There are
two approaches to bootstrapping results from a marginal mean
regression: the nonparametric bootstrap and the semiparametric
bootstrap. A detailed description of the bootstrap is outside the
scope of the current article; however, a good overview may be
found in a previous study [14]. Brieﬂy, the nonparametric boot-
strap quantiﬁes the sampling distribution of the statistic of inter-
est (e.g., a regression coefﬁcient) by creating a large number of
simulated datasets, each of which is used to estimate the statistic
of interest. The simulated datasets are created by sampling (with
replacement) individuals from the actual dataset. One drawback
to the nonparametric bootstrap is that it does not ﬁx the distri-
bution of the covariates, and so researchers may sometimes con-
sider the semiparametric bootstrap. In the semiparametric
bootstrap, instead of sampling the actual responses and covari-
ates from the original dataset, the bootstrap samples the residuals
from the linear model and ﬁxes the covariates. This has the
advantage of conditioning on the covariates; however, its validity
relies on being able to assume that the residuals from the linear
model are independent and identically distributed. The key
problem for utility data is that the residuals are unlikely to be
identically distributed because of the heteroscedascity in the data.
We illustrate this problem in the simulation study below.
Although work by Walters and Campbell [15] suggests that the
bootstrap yields similar results to t-tests and linear regressions,
we note that this was based on large datasets using individual
dimensions of the SF-36, which do not represent utilities.
There are a number of options for constructing conﬁdence
intervals based on bootstrap re-samples (see Kenward and Car-
penter [14] for a review). Here we shall consider two options:
using the bootstrap standard errors in place of the model-based
standard errors, and, in the case of the nonparametric bootstrap,
using the bias-corrected and accelerated (bca) bootstrap conﬁ-
dence intervals.
Robust standard errors. Robust standard error estimation poses
an alternative to the bootstrap when calculating P-values and
conﬁdence intervals. This method is designed to deal with het-
eroscedascity in the data and is suitable when sample sizes are
sufﬁcient for the regression coefﬁcients to be approximately
normal. The variance of the estimated regression coefﬁcients is
given by
var βˆ( ) = ′⎛⎝⎜ ⎞⎠⎟ ′ ′( )⎛⎝⎜ ⎞⎠⎟ ⎛⎝⎜ ⎞⎠⎟∑ ∑ ∑
−
X X X var Y X X X Xi i i
i
i i i i i
i i
1 −1
When heterosceascticity is present, var(Yi|Xi) is estimated by a
function of the residual Yi - Xib. The resulting covariance matrix
for βˆ is termed a heteroscedascticity consistent covariance matrix
(HCCM). There are a number of versions; however, here we shall
use the HCCM3 [16], which is designed to avoid observations
with large variances over-contributing to the analysis:
var βˆ β( ) = ′⎛⎝⎜ ⎞⎠⎟ −−⎛⎝ ⎞⎠ ′ ′⎛⎝⎜ ⎞⎠⎟∑ ∑
−
X X X
y X
h
X X Xi i i
i
i i
ii
i i i
i i
1 2
1 ∑⎛⎝⎜ ⎞⎠⎟
−1
where h X X X Xii i ij
j
j= ′′
⎛
⎝⎜
⎞
⎠⎟∑
−1
TPMs and LCMs. If the researcher does not want to consider
supranormal health states, an alternative to marginal linear
models is to model the distribution of observed utilities. Huang
et al. [9] consider TPMs and LCMs. The idea of both classes of
model is to divide the population into two parts, the ﬁrst of
which tend to have higher utilities, and the second have lower
utilities, so that the distribution of utilities in the total population
is a mixture distribution. In the TPM, the ﬁrst segment of the
population has utilities equal to 1, whereas in the LCM, both
segments have nontrivial distributions, and are distinguished
from one another by a latent classiﬁcation variable.
TPMs. Speciﬁcally, the TPM assumes that if Yi is the utility for
individual i, then
log it P Y X Xi i i=( )( ) =1 α
E Y X Y Xi i i i, <( ) =1 β
The TPM with a log transform explicitly acknowledges that if
an individual does not have Y = 1 then Y < 1 by using a log-
transform, namely
log , ,1 1 2−( ) <( ) ( )Y Y X N Xi i i i∼ β σ
LCMs. LCMs assume that observations fall into two or more
unobserved (latent) classes, and then model the distribution
within each class. In the context of utility data, which is fre-
quently bimodal, it will often be appropriate to assume that there
are two latent classes, and to adopt a normal distribution within
each class. If Ci is the latent class variable for individual i, with
Ci  {1,2}, the latent class model would be
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P C pi i=( ) −2
Y N X Ci i i∼ β σ1 12 1,( ) =if
Y N X Ci i i∼ β σ2 22 2,( ) =if 
Estimation of these models is typically via the expectation–
maximization algorithm (EM) [17].
Work by Huang et al. [8] suggests that for the speciﬁc dataset
studied, the TPM (with a log transform) and the LCM perform
the better than OLS and the TPM without a log transform, which
in turn perform better than CLAD, where the measures of per-
formance are the proportion of absolute deviation and square
deviation in the validation dataset explained by model predic-
tions derived from the training dataset. It should be noted that
the TPMs and LCMs are parametric approaches and each
assume normality. For the untransformed TPM, it is assumed
that the portion of the distribution below 1 follows a normal
distribution. For the transformed TPM, it is assumed that the
log-transformed portion of the distribution below 1 follows a
normal distribution. For the LCM, it is assumed that the distri-
butions within the classes are normally distributed. While for the
untransformed TPM and LCM, lack of normality is unlikely to
cause bias in the estimated regression coefﬁcients, serious bias
could result for the transformed TPM if inferences are to be made
about mean utilities on the untransformed scale.
4. Simulation Methods
This simulation study will explore the performance of the OLS,
Tobit, CLAD, two-part and latent class methods.
Dataset Used for Simulations
Diabetes Hamilton (Hamilton, ON, Canada) is a community-
oriented program that provides information and resources to
people with diabetes. At the time of registration, participants
consent to having some of their self-reported data included in a
registry and complete a ﬁve-page questionnaire, which is entered
centrally. Approximately 1000 Diabetes Hamilton participants
also completed the EQ5D at the time of registration. The follow-
ing simulation used EQ5D data and clinical data supplied by
1143 registrants in Diabetes Hamilton. The US scoring algorithm
was used to calculate the EQ5D utilities [18].
Simulation Model
For the purposes of illustration, we chose one to look at the
relationship between EQ5D and insulin. This variable was
chosen for two reasons: ﬁrstl, it is binary, making interpretation
straightforward, and second, a reasonable proportion of patients
reported using insulin, which made simulation more straightfor-
ward. The distribution of EQ5D in the Diabetes Hamilton
dataset is shown in Figure 1. This distribution is bimodal and
shows the usual ceiling effect, with 17% (193/1143) of the EQ5D
achieving the upper bound of 1. The minimum observed value of
the EQ5D is -0.03836. We used this dataset to simulate EQ5D
measurements following the empirical distribution observed in
the study. Speciﬁcally, we randomly sampled 50, 100, 200, and
500 patients from the database, and recorded their values of the
EQ5D and insulin. We also used the entire sample of 1141 with
valid EQ5D and covariate measurements (two individuals were
missing covariate data and were thus excluded). In each of the
1000 simulations, we ﬁrst selected 50 individuals from the
dataset of size 50 by sampling with replacement, then selected
100 individuals from the dataset of size 100, sampling with
replacement, and similarly for the sample sizes of 200, 500, and
1141. This procedure amounts to sampling from the empirical
distribution of the data for each given sample size, and is appeal-
ing as it avoids the need to make any distributional assumptions.
We added a very small random error to the EQ5D measurements
in each sampled datapoint (error ~ N(0, SD = 0.000001)) as this
led to fewer singularities in ﬁtting the CLAD model. When
adding this random error led to EQ5D values that were greater
than 1, these were truncated at 1.
We then computed the OLS, Tobit, CLAD, transformed two-
part, untransformed two-part and latent class estimators of the
unadjusted effect of taking insulin on utility, i.e., the estimators
of the regression coefﬁcient of insulin from a regression model of
EQ5D onto an intercept and insulin alone. This coefﬁcient is the
mean difference in EQ5D for those on insulin versus those not
taking insulin. Using the unadjusted coefﬁcient is useful for the
purposes of illustration, as in this simple case it is possible to
calculate what the true regression coefﬁcient for insulin should be
(i.e., the mean difference in utility between those on insulin vs.
those not on insulin); this is not the case when adjusting for other
covariates.
Criteria for Assessing Model Performance
Three criteria can be used to compare the models: bias, conﬁ-
dence interval coverage probability, and estimated standard
errors. These are described brieﬂy below. Because the TPMs and
LCMs do not provide estimates of standard errors of conﬁdence
intervals, these models are assessed in terms of their bias only.
Bias. The estimated bias in the coefﬁcients of insulin is deﬁned as
the mean value of the coefﬁcient across the 1000 samples minus
the true value.
The true coefﬁcient of insulin is derived by calculating
the difference in mean EQ5D among those on insulin versus
those not on insulin. The correct unadjusted coefﬁcients of
insulin are –0.008310555, –0.101493701, –0.089779487, and
–0.066055266 for the subsamples of 50, 100, 200, and 500
patients, respectively; and –0.078575287 for the sample as a
Figure 1 Histogram of EQ5D scores in the Diabetes Hamilton dataset, using
US scoring.
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whole. It may seem surprising that all these coefﬁcients are nega-
tive, so that patients on insulin have lower utilities than those
who are not. However, this is an observational study and the
coefﬁcients are unadjusted, so it is likely that patients who
require insulin therapy are in worse health than those who do
not.
In examining bias statistics, clearly we would like the bias to
be zero. Because we are limited to a ﬁnite number of simulations,
our results will be subject to sampling variation, and so in addi-
tion to reporting bias, we report the bias divided by its standard
error (which is equal to the standard error of the mean of the
regression coefﬁcients). If an estimation technique is unbiased,
we would expect the observed bias divided by its standard error
to lie between –1.96 and +1.96 95% of the time.
Coverage probability. In addition to calculating bias, we will
also look at how adequate the 95% conﬁdence intervals for the
estimated coefﬁcients of insulin are. Coverage probability is
deﬁned as the proportion of times that the estimated 95% con-
ﬁdence interval contains the true value of the regression coefﬁ-
cient. Then, if the conﬁdence intervals are correct, we expect the
coverage probability to be 0.95. Again, because we are limited to
a ﬁnite number of simulations, we will not see exactly 95%
coverage, but with 1000 simulations we would expect the
observed coverage probability to lie between 93.6 and 96.4%
95% of the time. Coverage probabilities are available only for
the linear regression, Tobit, and CLAD models, as the other
methods do not return standard errors or conﬁdence intervals for
the estimated mean difference in utility between those on insulin
versus those not on insulin.
Empirical standard errors (ESEs) and average estimated standard
errors (ASEs). In order to understand any departures of the
coverage probabilities from the required 0.95, it is helpful to
look at estimates of standard error. For each estimator, the ESE
is the standard deviation of the 1000 estimates of the unad-
justed regression coefﬁcient for insulin. The ASE is the average
of the model-based standard errors for each of the 1000 simu-
lations. If the model-based standard errors are correct, the ASE
should be close to the ESE. As with the coverage probabilities,
ASEs will be available only for the linear regression, Tobit and
CLAD models.
5. Simulation Results
Table 2 shows that if we are interested in the association between
insulin and utility, the Tobit, CLAD, and transformed TPM are
biased, but the OLS, untransformed two-part, and latent class
estimators are unbiased. The extent of the bias does not appear
to depend on sample size. Bias becomes easier to detect for larger
sample sizes because as the sample size increases, the standard
error of the estimated bias decreases, so that when important bias
is present the estimated bias divided by its standard error
increases with increasing sample size.
Table 3 shows that the OLS, Tobit, and CLAD methods yield
conﬁdence intervals that have coverage probabilities that are in
general too low, dramatically so for the CLAD. In the case of the
CLAD method, this can be explained by the bias. In the case of
the Tobit, the undercoverage could be due to bias, to heterosce-
dascity, or to nonnormality. In the case of OLS, the undercover-
age could be due to either heteroscedascity or to nonnormality.
Undercoverage of the conﬁdence intervals corresponds to conﬁ-
dence intervals that are too narrow, and hence P-values that are
anticonservative. For example, for the OLS estimator with a
sample size of 1141, the coverage probability of 0.927 means
that the model-based P-value would be 0.05 when the true
P-value was 0.073. Thus, the error in the conﬁdence intervals
and P-values is in fact very serious and would lead to seriously
inﬂated type I errors.
Examining the empirical and estimated standard errors of the
regression coefﬁcients helps to explain the observed coverage
probabilities. Table 4 shows that for the OLS and Tobit estima-
tors, the empirical standard errors are all larger than the esti-
mated standard errors. Thus, the model-based standard errors
are too small, which has led to conﬁdence intervals that are too
narrow.
We now explore the role of robust standard errors and boot-
strapping for the marginal linear model. Semiparametric boot-
strapping has been suggested for OLS estimators; however, it is
not recommended as it leads to coverage probabilities that are
too low (see Table 5). This is because semiparametric bootstrap-
Table 2 Bias (and bias/ses) statistics for the OLS,Tobit, CLAD, two-part, and latent class estimators
Sample
Size OLS Tobit CLAD
TPM
trans
TPM
No trans LCM
50 -0.00068 -0.00252 -0.00108 -7439.15 -0.00068 -0.00068
(-0.34) (-1.17) (-0.72) (-1.30) (-0.34) (-0.34)
100 0.00012 -0.00327 0.05721 -29.92 0.00012 0.00014
(0.11) (-2.95) (64.10) (-9.26) (0.11) (0.13)
200 -0.00170 -0.01034 0.03497 -711.44 -0.00170 -0.00167
(-1.77) (-10.23) (34.14) (-16.39) (-1.77) (-1.74)
500 -0.00030 -0.00482 0.03433 -136.00 -0.00030 -0.00031
(-0.47) (-7.09) (54.93) (-24.32) (-0.47) (-0.48)
1141 0.00049 -0.00587 0.04225 -153.66 0.00049 0.00049
(1.11) (-12.76) (85.67) (-43.21) (1.11) (1.12)
The ﬁrst number in each cell is the estimated bias, i.e., the mean estimate of the regression coefﬁcient of insulin across the 1000 simulations, minus its true value.The second number (in
parentheses) is the estimated bias divided by its standard error. If the estimator is unbiased, bias/se should be between -1.96 and +1.96 with probability 0.95.The numbers are bias with ratio
of bias to standard error in parenthesis.
CLAD, censored least absolute deviations; LCM, latent class model; OLS, ordinary least squares;TPM, two-part model.
Table 3 Coverage probabilities of the 95% conﬁdence intervals for the
OLS,Tobit, and CLAD estimators
Sample Size OLS Tobit CLAD
50 0.939 0.939 0.660
100 0.922 0.924 0.217
200 0.950 0.942 0.725
500 0.941 0.943 0.272
1141 0.927 0.921 0.029
If the conﬁdence intervals are correct, the coverage probabilities should all be 0.95.
CLAD, censored least absolute deviations; OLS, ordinary least squares.
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ping assumes that the residuals are homoscedasctic, which is not
the case in this example. By contrast, the robust standard errors
and nonparametric bootstrap bca intervals give acceptable cov-
erage probabilities for the OLS estimator for sample sizes of 100
or larger, while replacing the model-based standard errors with
the nonparametric bootstrap standard errors gives acceptable
coverage probabilities for sample sizes of 200 or larger.
When it is health utilities rather than HRQoL that are of
interest, linear regression is not the only option. Table 6 explores
the relative efﬁciency, in terms of estimated standard errors, of
the linear regression, untransformed two-part and a latent class
estimators. All three methods have comparable variability, which
is not surprising as in this case we have just a single binary
covariate, and it is well known that the OLS estimators are
BLUE.
6. Discussion
Previous work has advocated the use of Tobit or CLAD models
for the analysis of HRQoL data when the primary focus is on
regression modeling, understanding the relationship between
HRQoL and a covariate, or on explaining variability in HRQoL
[6,7]. This approach has, however, also been adopted when
analyzing health utility data for the purposes of economic evalu-
ation. In this context, Tobit and CLAD models are not appro-
priate as they assume that utilities can extend beyond 1, when in
fact for the EQ5D or HUI health states are scored according to
empirically estimated utilities, treating 1 as the maximum score.
Our simulations show that when the utility must be bounded
above at 1, the Tobit and CLAD models both lead to bias.
When utilities are not treated as having been observed subject
to censoring, the analysis must deal with the conditional non-
normality and heteroscedascity of the data. OLS gives unbiased
estimators of regression parameters regardless of distributional
assumptions; however, the estimated standard errors will usually
not be correct even for large sample sizes because they are cal-
culated based on the assumption of homoscedascity. A simple
solution is to use a robust standard error or the nonparametric
bootstrap. Some authors [15] have suggested a semiparametric or
parametric bootstrap based on re-sampling the residuals;
however, this is not appropriate as it assumes that the residuals
all have equal variance. This is borne out by our simulation
study, which shows that for our data, the semiparametric boot-
strap led to conﬁdence intervals that were too narrow.
While OLS coupled with the bootstrap or robust standard
errors provides asymptotically unbiased regression coefﬁcients
and valid conﬁdence intervals, the estimates may not be as
precise as they could be. The reason for this is that OLS ﬁts a
marginal model, that is, a model for the mean utility, not for the
whole distribution. Generally, if a good model for the data dis-
tribution could be found, one would expect that it would yield
more precise estimates of the relevant regression coefﬁcients.
Various alternatives have been proposed, among them are beta
distributions, TPMs, and LCMs.
Beta models are an appealing strategy because they assume
that utilities are bounded above at 1; however, they also assume a
lower bound of 0, which may not be appropriate for all popula-
tions. For example, in our population, the minimum EQ5D was in
fact negative. TPMs are useful in describing the ceiling effect. The
drawback, however, is that if we are interested in means, they are
not direct outputs of the model, especially when more than one
covariate is considered in the linear regression. In our simulation
example, the transformed TPM was biased because the assump-
tion of normality and homoscedascticity of the log-transformed
utilities was not met. The untransformed TPM was unbiased and
showed similar precision to linear regression. This precision result
is, however, sensitive to the distribution of the data and hence will
not necessarily hold in general.
LCMs are an attractive alternative when the distribution of
utility scores is bimodal. There is thus nothing in the model that
stipulates that utility scores should be bounded; however divid-
ing the population into subgroups can help to ensure that the
model-based probability of an individual falling outside of the
bounds is small. Huang et al. found that TPMs and LCMs out-
performed OLS in terms of minimizing residual sums of squares
[8]. In our simulation example, LCMs were no more precise than
Table 4 ESE and ASE for the OLS,Tobit, and CLAD methods
Sample
Size
OLS Tobit CLAD
ESE ASE ASE/ESE ESE ASE ASE/ESE ESE ASE ASE/ESE
50 0.064 0.063 0.993 0.068 0.067 0.981 0.048 0.060 1.269
100 0.034 0.031 0.898 0.035 0.032 0.903 0.028 0.015 0.530
200 0.030 0.030 0.976 0.032 0.032 1.001 0.032 0.040 1.241
500 0.020 0.020 0.975 0.021 0.021 0.996 0.020 0.015 0.783
1141 0.014 0.013 0.926 0.015 0.014 0.950 0.016 0.007 0.475
The ESE is the standard deviation of the estimated regression coefﬁcients over the 1000 simulations.TheASE is the standard error estimate for the regression coefﬁcients returned by the model,
averaged over the 1000 simulations. If the model-based estimate of the standard error is correct, the ASE and the ESE should be close.
ASE, average estimated standard error; CLAD, censored least absolute deviations; ESE, empirical standard error; OLS, ordinary least squares.
Table 5 OLS coverage probabilities using the model-based, robust, and semiparametric and nonparametric bootstrap standard errors, and the
nonparametric bootstrap bca conﬁdence intervals
Sample
size Model-based Robust
Semiparametric
bootstrap
Nonparametric bootstrap
standard errors
Nonparametric bootstrap
bca intervals
50 0.939 0.934 0.928 0.930 0.909
100 0.922 0.950 0.925 0.934 0.964
200 0.950 0.945 0.952 0.948 0.950
500 0.941 0.953 0.939 0.946 0.945
1141 0.927 0.944 0.925 0.940 0.94
bca, bias-corrected and accelerated; OLS, ordinary least squares.
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linear regression in terms of the sample standard error, however
as with the TPM, it is important to recognize that the relative
efﬁciency of latent class and linear regression models will be
speciﬁc to the data and models under consideration.
Our simulation analysis has its limitations. The simulation
parameters were generated using utilities derived from the EQ5D
measured in a diabetic population in Canada. The distribution of
utilities, especially the extent of the ceiling effect, will vary when
studying different populations, or using a different measure of
utility (e.g., the HUI). Populations who are sicker will exhibit a
smaller ceiling effect, and thus the differences between the OLS,
Tobit and CLAD models will likely diminish. Conversely, popu-
lations in better health will exhibit larger ceiling effects, which
will increase the differences between the estimators. However, the
philosophical point remains that it does not make sense to treat
utilities as censored at 1 when the intent is to inform an economic
evaluation. Similarly, whatever the population, the mathematical
point remains that treating utilities as censored at 1 results in
estimating the wrong parameters.
In this article, we have adopted the widely-held convention
that the anchor points for health utilities are death and full
health. We do, however, acknowledge that while death is a con-
crete state, each individual has their own notion of what consti-
tutes full health. We also acknowledge that there is a school of
thought whereby there exists a better-than-full health state
which, it is argued, should have a utility that exceeds 1 (and
hence, that an individual in this health state should accrue more
than one QALY in a single year). A detailed discussion of this
issue is beyond the scope of this article; however, we make the
following observations. First, if better-than-full health states do
indeed have utilities that exceed one, then when health utility is
captured using the EQ5D or the HUI, the observed measure-
ments are indeed censored. Second, if the outcome of interest is
mean health utility (or mean QALYs), then neither the Tobit nor
the CLAD model provides an acceptable solution. The CLAD
models medians rather than means, and these two statistics will
in general be different. The Tobit model assumes normality of the
uncensored measurements, and it is impossible to demonstrate
normality in the upper, unobserved tail of the utility
distribution—we cannot assess normality in something we do not
see. This motivates our third observation, namely that if such
better-than-full health states exist, their associated utilities
should be estimated through population TTO or SG studies in
the same manner that utilities for other health states have been
estimated. We reiterate, however, that the commonly-held inter-
pretation is that utilities are bounded above at one, and that
small departures from full health (and hence utilities which are
just below one) are not captured by our measurement instru-
ments. This results in a nonnegligible proportion of the popula-
tion attaining the upper bound.
In conclusion, we note that Tobit and CLAD models, which
assume that utilities can exceed 1, are not appropriate when the
outcome of interest is a health utility that will be used in order to
calculate QALYs for use in an economic analysis. OLS coupled
with robust standard errors or the nonparametric bootstrap is
asymptotically unbiased and produces valid conﬁdence intervals.
Moreover, it is easy to implement using standard software.
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Table 6 Comparison of empirical standard errors among methods
appropriate for health utility data
Sample
size OLS
Untransformed
TPM LCM
50 0.064 0.064 0.064
100 0.034 0.034 0.034
200 0.030 0.030 0.030
500 0.020 0.020 0.020
1141 0.014 0.014 0.014
These numbers are the observed standard deviation of estimated difference in utility for
those using insulin versus those not using insulin among the 1000 simulated datasets.
LCM, latent class model; OLS, ordinary least squares;TPM, two-part model.
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